QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio
Acquisition strengthens QIAGEN’s presence in the rapidly growing single-cell market
19 Nov 2025
QIAGEN has announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research.
The acquisition will significantly expand QIAGEN’s Sample technologies portfolio into the fast-growing single-cell sequencing market with highly scalable chemistry designed to power research involving up to millions and billions of cells.
Parse’s scalable chemistry is also expected to accelerate growth in the QIAGEN Digital Insights (QDI) bioinformatics business, enabling customers to generate, process and interpret AI-driven single-cell data more efficiently and at much greater scale, from the first sample to actionable insights.
Single-cell analysis allows scientists to study the activity of genes in individual cells, revealing the driving mechanisms of health and disease. This expansion is being driven by AI-based drug discovery as pharmaceutical and biotechnology companies generate large-scale cellular datasets to train predictive models of biology.
Parse is distinctly positioned to capitalize on this trend with Evercode, a proprietary combinatorial barcoding platform. Evercode is highly differentiated by enabling large-scale projects to analyze millions and billions of cells, a capability lacking in other single-cell offerings. Parse’s technologies are supporting breakthroughs by generating the massive datasets required to power a new generation of discovery.
Parse’s technology is designed to profile more cells in less time, addressing the increasing demand among customers for massive-scale projects, particularly in pharma and academia.
Key advantages include:
- Instrument-free: Parse solutions do not require a specialized instrument, allowing for rapid customer adoption and use in any lab and creating a major differentiator in scalability.
- Data scale and quality: Parse has pioneered high-throughput single-cell analysis, highlighted by the Tahoe-100M dataset – the largest publicly available single-cell dataset to date comprising more than 100 million single-cell transcriptomes (the complete set of RNA molecules expressed in each cell).
- GigaLab service: Parse’s latest offering is GigaLab, a high-throughput service with a capacity of 2.5 billion cells per year. This service supports multi-million cell projects used in drug and target screens across therapeutic areas such as oncology, immunology and neurology, and is highly valued by pharmaceutical partners.
- Broad adoption: Parse’s products are used by over 3,000 labs globally, including all of the top 50 research institutions and top 10 pharma companies.
- Intellectual property: Parse holds an exclusive license to 36 granted University of Washington patents on split-pool combinatorial barcoding for all fields, providing broad protection for its proprietary technology.
“The addition of the Parse team to QIAGEN will significantly strengthen our offerings in one of the most dynamic areas of life science,” said Thierry Bernard, CEO of QIAGEN. “Single-cell analysis is the key to understanding health and disease at a mechanistic level. By combining Parse with our Sample technologies portfolio and QDI bioinformatics offering, we can provide researchers with the tools to generate the massive datasets required to build predictive virtual cell models that fuel AI-based drug discovery.”